|Bid||77.92 x 100|
|Ask||81.32 x 100|
|Day's Range||78.55 - 79.75|
|52 Week Range||73.69 - 89.09|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.25 (2.82%)|
|1y Target Est||N/A|
Gilead Sciences Inc. shares dropped 2.1% in moderate Thursday trade after a Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co. and Incyte Corp. drug. ...
Eli Lilly & Co. shares fell 1.8% premarket and Incyte Corp. shares dropped 4.5% premarket on Thursday after a Food and Drug Administration briefing document raised issues with their rheumatoid arthritis drug baricitinib. The drug will go up before a FDA arthritis advisory committee meeting on Monday. The FDA often follows an advisory committee's recommendation, though there are exceptions.
Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products.
Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.
Headquartered in Basel, Switzerland, Novartis (NVS) is one of the largest pharmaceutical companies by revenue. Novartis specializes in the development, manufacturing, and marketing of healthcare products.
In December 2017, AbbVie (ABBV) announced positive top-line results for its pivotal Phase 3 IMMhance trial to evaluate the safety and efficacy of risankizumab 150 mg1 for the treatment of individuals with moderate-to-severe plaque psoriasis.
Merck's (MRK) Keytruda significantly prolongs RFS and reduces the risk of disease recurrence or death by 43% versus placebo in a phase III study in high-risk stage III melanoma patients.
Shares of Eli Lilly & Co. rallied 1.2% in morning trade Friday, after BMO Capital backed away from its bearish stance that it's kept for the past year, given the belief that previous concerns are now mostly ...
In February 2017, Eli Lilly (LLY) secured approval for Olumiant (baricitinib) from the European Medicines Agency (or EMA) for patients suffering from moderate-to-severe rheumatoid arthritis (or RA) and who did not respond sufficiently or could not tolerate disease-modifying antirheumatic drugs (or DMARDs). In July 2017, the drug was approved by the Japan Ministry of Health, Labor, and Welfare for RA patients who don’t respond sufficiently to standard-of-care treatment options. The drug is also approved in Switzerland for the RA indication.
Incyte (INCY) expects to report GAAP (generally accepted accounting principles) and non-GAAP revenues in the range of $80 million to $85 million from the sale of Iclusig in fiscal 2018. In June 2016, Incyte entered a licensing agreement with Ariad Pharmaceuticals for the development and commercialization of kinase inhibitor, Iclusig, in the European Union and 22 other countries.
Novartis AG (NVS) reported EPS (earnings per share) of $1.21 on revenue of ~$12.9 billion in 4Q17, a 5% rise compared to $12.3 billion in 4Q16. Novartis is expected to report revenue of $12.5 billion in 1Q18 compared to $11.5 billion in 1Q17. On April 11, 2018, Novartis was trading at a forward PE of ~14.9x.
In 2017, Incyte (INCY) reported total revenues of close to $1.5 billion, which was year-over-year (or YoY) growth of around 38.9%. The company earned revenues close to $1.1 billion from the sale of Jakafi, a JAK1/JAK2 inhibitor, in the US, and $152 million as royalties received from Novartis (NVS) on the sale of Jakafi, marketed as Jakavi, in international markets. Wall Street analysts have projected Incyte’s fiscal 2018 revenues to be close to $1.8 billion, which is a YoY rise of around 16.9%.
Eli Lilly and Company (LLY) is a US pharmaceutical company with headquarters in Indianapolis, Indiana. The company specializes in products for both human health and animal health.
AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication.
Bristol-Myers Squibb (BMY) is an American pharmaceutical company with headquarters in New York City. Bristol-Myers Squibb specializes in cardiovascular products, immunoscience products, neuroscience products, oncology products, and virology products.
Both of these pharmaceutical giants are trading at cheap valuations and offer big dividends, due to troubles that are mostly behind them.
Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study
A late-stage study evaluating Eli Lilly's (LLY) Cyramza for the second-line treatment of liver cancer patients shows that such patients derived a survival benefit with Cyramza after first-line treatment with Nexavar.
The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.
A battle brewing in liver cancer will land Exelixis on top, an analyst said Wednesday after rival Eli Lilly posted strong topline results for its drug.